Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study

RT @jsross119: Erick's paper demonstrates. Reporting biases are diminished for newer vs older antidepressants! Bonus content, (ICYMI) we've…

Erick's paper demonstrates. Reporting biases are diminished for newer vs older antidepressants! Bonus content, (ICYMI) we've also examined FDAAA's impact for various drug classes & medical devices (2/2) https://t.co/kG4u5QAgbN, https://t.co/TCCmbksQ2C,

We had previously shown that FDAAA was associated with higher rates of trial registration and results reporting on https://t.co/ickEwc8kA2 and significantly lower degrees of publication bias for drug trials (2/5) https://t.co/5dpAXjVVN7 and https://t.co/TC

RT @cxzou1: Reasons to be hopeful for a less biased literature: Our study showed significantly improved reporting of negative psych drug st…